Purpose Mechanical sag in the radiotherapy linear accelerator gantry and multi‐leaf collimator (MLC) carriage effectively causes systematic deviations in the isocenter with respect to gantry angle. To minimize the impact of this error on treatment, a tolerance value of a 1‐mm mechanical isocenter shift is commonly accepted for intensity‐modulated radiation therapy quality assurance (QA). However, this tolerance value has not been firmly established for volumetric modulated arc therapy (VMAT) treatments. The purpose of this study is therefore to evaluate the impact of gantry and MLC carriage sag on VMAT clinical performance. Methods A published dataset of Elekta and Varian sag measurements served as a starting point for the investigation. Typical sag profiles were chosen and modeled as continuous isocenter deviations in three dimensions. The data were then incorporated into existing Digital Imaging and Communications in Medicine protocol, extended for radiotherapy plans via a “beam‐splitting” algorithm. Three treatment sites were investigated in parallel: head and neck, prostate, and prostate with surrounding lymph nodes. Monte Carlo‐simulated dose distributions were obtained for varying magnifications of the modeled sag. The resulting dose distributions, including that for no error, were compared qualitatively and quantitatively, against multiple metrics. Results The dose‐volume histograms (DVHs) for all plans exhibited a decrease in planning target volume (PTV) dose uniformity with increasing sag magnification, whereas dose to organs at risk exhibited no coherent trend. The prostate plan was shown to be the most vulnerable to mechanical sag across all considered metrics. However, all plans with peak isocenter deviation less than 1 mm were well within typical cutoff points for each metric. Conclusions All avenues of investigation presented substantiate the commonly accepted tolerance value of a 1‐mm peak isocenter shift in annual linac QA.
ObjectiveCurrent accepted linac Quality Assurance (QA) guidelines used for Volumetric Modulated Arc Therapy (VMAT) suggest a mechanical isocentre tolerance level of 1 mm. However, this tolerance level has not been well-established for the specific case of small field stereotactic VMAT. This study aims to evaluate the clinical impact of mechanical uncertainty on this treatment modality by modelling systematic gantry sag derived isocentre variance in the Treatment Planning System (TPS).ApproachA previously reported dataset of gantry sag values in the literature served as a starting point for this study. Using an in-house developed VMAT arc splitting algorithm, isocentre shifts were applied at a Control Point (CP) level to DICOM-RT treatment plans. Dose distributions for varying isocentre shift magnitudes were calculated for a set of 29 stereotactic VMAT plans using the Eclipse Acuros XB dose algorithm. These plans had a range of Planning Target Volume (PTV) sizes. A quantitative comparison of each plan was conducted by evaluating five Dose Volume Histogram (DVH)-derived plan quality metrics.ResultsAll metrics exhibited a deterioration in plan quality with increasing magnitudes of isocentre shift. At small PTV sizes, these effects were amplified, exhibiting significant changes at 1 mm of average shift when typical targets and tolerances were considered. For plans with PTVs between 0 and 5 cm3, a 1 mm shift reduced PTV coverage by 6.6 ± 2.2% and caused a 12.1 ± 3.8% deterioration in the conformity index. Based on the results of this study, the prevalent tolerance of 1 mm may not be suitable for treatments of small PTVs with small fields.SignificanceIn contrast to commonly accepted values, an absolute mechanical isocentre of 0.5 mm with action level at 0.75 mm is recommended for stereotactic VMAT of PTV sizes below 10 cm3.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.